{"id":724609,"date":"2026-04-29T15:30:24","date_gmt":"2026-04-29T12:30:24","guid":{"rendered":"https:\/\/buradabiliyorum.com\/en\/munichs-mbiomics-closes-e30m-to-develop-live-bacterial-product\/"},"modified":"2026-04-29T15:30:24","modified_gmt":"2026-04-29T12:30:24","slug":"munichs-mbiomics-closes-e30m-to-develop-live-bacterial-product","status":"publish","type":"post","link":"https:\/\/buradabiliyorum.com\/en\/munichs-mbiomics-closes-e30m-to-develop-live-bacterial-product\/","title":{"rendered":"Munich\u2019s mbiomics closes \u20ac30M to develop live bacterial product"},"content":{"rendered":"
\n

The Munich techbio company is developing a live bacterial product designed to enhance immune checkpoint inhibitor response in advanced melanoma, with a Phase 1B study planned for 2027<\/span><\/i><\/p>\n\n

mbiomics GmbH<\/a>, a Munich-based techbio company developing microbiome-based therapeutics, has completed the third and final closing of its Series<\/a> A funding round, bringing the total raised to \u20ac30 million. <\/span><\/p>\n

The latest \u20ac12 million tranche was provided by existing investors MIG Fonds and Bayern Kapital, and marks the conclusion of a round that began in March 2023.<\/span><\/p>\n

The capital will fund two near-term priorities: strengthening the IND-enabling pharmacological data package for the company\u2019s lead candidate MBX-116, and accelerating the GMP-grade manufacturing development required to produce it at the clinical scale needed for human trials. The goal is a Phase 1B study in second-line advanced melanoma, planned to begin in 2027.<\/span><\/p>\n

\u201cWhile the clinical potential of the gut microbiome is well understood, transforming microbiome-based therapeutics into a scalable product has remained a significant engineering challenge,\u201d<\/em> said Dr. Johannes B. Woehrstein, CEO and co-founder of mbiomics. <\/span><\/p>\n

\n
\n
<\/div>\n

<\/p>\n

\n

The \ud83d\udc9c of EU tech<\/p>\n

The latest rumblings from the EU tech scene, a story from our wise ol’ founder Boris, and some questionable AI art. It’s free, every week, in your inbox. Sign up now!<\/p>\n<\/div>\n<\/div>\n<\/div>\n

\u201cAt mbiomics, we are solving this challenge by building the full technology<\/a> stack for the design, analysis, screening, and manufacturing of complex microbial consortia.\u201d<\/em><\/span><\/p>\n

Founded in Munich in 2020 by Woehrstein, Dr. Markus Rinecker, and Dr. Laura Figulla, mbiomics sits at the intersection of microbiology, AI-driven drug design, and precision medicine. <\/span><\/p>\n

Its core product class is Live Biotherapeutic Products (LBPs), oral therapeutics composed of defined combinations of live bacterial strains, delivered in a pharmaceutical-grade format. <\/span><\/p>\n

The distinction from earlier-generation microbiome interventions matters: faecal microbiota transplants (FMTs) have demonstrated clinical efficacy across multiple conditions but are inherently variable, non-standardised, and difficult to manufacture at scale. mbiomics\u2019 platform is designed to replace FMT\u2019s empirical variability with a rationally designed, reproducible product.<\/span><\/p>\n

The platform combines AI and machine-learning-driven consortia design, proprietary high-resolution analytical technology, and large-consortium co-cultivation and screening capabilities. <\/span><\/p>\n

The AI layer is used not just to identify candidate bacterial strains but to design the specific combination, the consortia, most likely to produce a defined therapeutic effect in a defined patient population. <\/span><\/p>\n

This app<\/a>roach to rational consortia design, rather than single-strain probiotics or empirical transplants, is where mbiomics positions itself as a step-change from what came before it.<\/span><\/p>\n

mbiomics\u2019 lead clinical target, MBX-116 as a co-therapy alongside immune checkpoint inhibitors in second-line advanced melanoma, is grounded in a well-established but still-developing body of clinical evidence. <\/span><\/p>\n

The gut microbiome modulates the immune system through multiple mechanisms: microbial metabolites, including short-chain fatty acids and tryptophan-derived compounds, regulate immune cell activation, dendritic cell activity, and the development of regulatory T cells, collectively shaping whether the immune system mounts a strong enough anti-tumour response.<\/span><\/p>\n

Clinically, the relationship between microbiome composition and checkpoint inhibitor response has been documented in several studies. A landmark trial by Routy et al. found that FMT from ICI-responsive donors significantly improved outcomes in patients with refractory melanoma, with objective response rates reaching 65% in some cohorts. <\/span><\/p>\n

Conversely, patients who had received broad-spectrum antibiotics within 30 days of starting checkpoint inhibitor therapy, which disrupts the gut microbiome, consistently showed worse outcomes across multiple tumour types. <\/span><\/p>\n

Specific bacterial taxa, including <\/span>Akkermansia muciniphila and Faecalibacterium prausnitzii<\/span><\/a>, have been repeatedly identified as enriched in ICI responders and mechanistically linked to enhanced effector T cell activity.<\/span><\/p>\n

The \u20ac30 million total is relatively modest by the standards of late-preclinical biotech rounds, but mbiomics is an IND-stage company: it is still completing the pharmacological data package required to file an Investigational New Drug application with regulators. <\/span><\/p>\n

The Phase 1B trial target of 2027 gives the company approximately 18 months from now to reach IND submission and trial initiation, an achievable timeline for a company at this stage if GMP manufacturing comes together on schedule.<\/span><\/p>\n

Beyond oncology, mbiomics has described a broader pipeline of microbiome-based therapeutics targeting indications including autoimmune and neurodegenerative diseases, indications where the gut\u2013brain axis and gut\u2013immune axis connections have generated increasing research interest but where no therapeutic-grade LBP has yet reached late-stage clinical development. <\/span><\/p>\n

If the company pursues those indications independently or in partnership will likely be shaped by the results of the melanoma trial.<\/span><\/p>\n<\/p><\/div>\n

If you liked the article, do not forget to share it with your friends. Follow us on\u00a0Google News<\/a><\/span>\u00a0too, click on the star and choose us from your favorites.<\/span><\/strong><\/p><\/blockquote>\n

\n

If you want to read more like this article, you can visit our Technology category.<\/a><\/span><\/strong><\/p>\n<\/blockquote>\n

Source<\/a><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

The Munich techbio company is developing a live bacterial product designed to enhance immune checkpoint inhibitor response in advanced melanoma, with a Phase 1B study planned for 2027 mbiomics GmbH, a Munich-based techbio company developing microbiome-based therapeutics, has completed the third and final closing of its Series A funding round, bringing the total raised to…<\/p>\n","protected":false},"author":1,"featured_media":724610,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/media.thenextweb.com\/2026\/04\/mbiomics.avif","fifu_image_alt":"","footnotes":""},"categories":[18],"tags":[],"class_list":["post-724609","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology"],"_links":{"self":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/posts\/724609","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/comments?post=724609"}],"version-history":[{"count":0,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/posts\/724609\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/media\/724610"}],"wp:attachment":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/media?parent=724609"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/categories?post=724609"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/tags?post=724609"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}